Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

OBJECTIVE: Choosing therapies for type 2 diabetes that are both effective and cost-effective is vital as healthcare systems worldwide aim to maximize health of the population. The present analysis assessed the cost-effectiveness of once-weekly semaglutide (a novel glucagon-like peptide-1 (GLP-1) rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Barnaby, Malkin, Samuel J P, Moes, Robert G J, Huisman, Eline L, Vandebrouck, Tom, Wolffenbuttel, Bruce H R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777406/
https://www.ncbi.nlm.nih.gov/pubmed/31641522
http://dx.doi.org/10.1136/bmjdrc-2019-000705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777406/
https://www.ncbi.nlm.nih.gov/pubmed/31641522
http://dx.doi.org/10.1136/bmjdrc-2019-000705

Ejemplares similares